Related Experiment Video
Updated: Jul 3, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Chemotherapy drug response in ovarian cancer cells strictly depends on a cathepsin D-Bax activation loop
Roberta Castino1, Claudia Peracchio, Alessandra Salini
1Department of Medical Sciences, "A. Avogadro" University, Novara, Italy.
Abstract:
The ovarian cancer cell lines A2780 (wild-type p53) and NIHOVCAR3 (mutated p53) showed, respectively, sensitivity and resistance towards several chemotherapy drugs. We hypothesized that the two cell lines differ in their ability to activate the intrinsic death pathway and have, therefore, dissected the lysosome-mitochondrion signalling pathway by pharmacological inhibition or genetic manipulation of key regulators and executioners. Biochemical and morphological confocal fluorescence studies showed that: (1) In A2780 cells bcl-2 is expressed at an undetectable level, whereas Bax is expressed at a rather high level; by contrast, bcl-2 is highly expressed and Bax is expressed at extremely low levels in NIHOVCAR3 cells; (2) Chemotherapy treatment reduced the expression of bcl-2 in NIHOVCAR3 cells, yet these cells resisted to drug toxicity; (3) Cathepsin D (CD), not cathepsin B or L, mediates the activation of the mitochondrial intrinsic death pathway in A2780 cells; (4) Lysosome leakage and cytosolic relocation of CD occurs in the chemosensitive A2780 cells, not in the chemoresistant NIHOVCAR3 cells; (5) Bax is essential for the permeabilization of both lysosomes and mitochondria in A2780 cells exposed to chemotherapy drugs; (6) CD activity is mandatory for the oligomerization of Bax on both mitochondrial and lysosomal membranes; (7) Bax activation did not occur in the resistant NIHOVCAR3 cells despite their high content in CD. The present data are consistent with a model in which on treatment with a cytotoxic drug the activation of a CD-Bax loop leads to the generalized permeabilization of lysosomes and eventually of mitochondria, thus reaching the point of no return, and culminates with the activation of the caspase cascade. Our data also imply that dysfunctional permeabilization of lysosomes contributes to the development of chemoresistance.
Insights
Chemosensitive ovarian cancer cells activate a Cathepsin D (CD)-Bax pathway, leading to lysosome and mitochondrial permeabilization. Chemoresistant cells bypass this, highlighting lysosomal dysfunction in drug resistance.
Area of Science:
- Cell Biology
- Cancer Research
- Biochemistry
Background:
- Ovarian cancer cell lines A2780 (wild-type p53) and NIHOVCAR3 (mutated p53) exhibit differential sensitivity to chemotherapy.
- The intrinsic cell death pathway's activation mechanism in response to chemotherapy remains incompletely understood.
Purpose of the Study:
- To investigate the role of the lysosome-mitochondrion signaling pathway in chemoresistance.
- To elucidate the molecular mechanisms underlying differential drug sensitivity in ovarian cancer cells.
Main Methods:
- Pharmacological inhibition and genetic manipulation of key regulators in the lysosome-mitochondrion pathway.
- Biochemical assays and confocal fluorescence microscopy to study protein expression and localization.
- Analysis of cell viability and apoptosis markers following chemotherapy treatment.
Main Results:
- Chemosensitive A2780 cells showed high Bax and low Bcl-2 expression, while resistant NIHOVCAR3 cells had high Bcl-2 and low Bax.
- Cathepsin D (CD) mediated mitochondrial death pathway activation in A2780 cells.
- Lysosome leakage and cytosolic CD relocation occurred in chemosensitive cells, but not resistant cells.
- Bax was essential for lysosomal and mitochondrial permeabilization, and CD activity was mandatory for Bax oligomerization in A2780 cells.
Conclusions:
- A Cathepsin D-Bax signaling loop drives lysosomal and mitochondrial permeabilization, initiating apoptosis in chemosensitive ovarian cancer cells.
- Dysfunctional lysosomal permeabilization contributes to chemoresistance in ovarian cancer.
- Targeting the CD-Bax pathway could offer novel therapeutic strategies for overcoming ovarian cancer chemoresistance.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway
Inhibition of Cdk Activity